Drug intelligence / Profile preview

CB-301

Development stage: Preclinical
Lead developer: Cantabio Pharmaceuticals
Modality: Small Molecules

Overview

CB-301 is a small molecule drug under development by Cantabio Pharmaceuticals. It acts as an inhibitor of microtubule-associated protein tau (TAU), targeting the pathological aggregation or function of tau protein. The primary therapeutic area for this drug is nervous system diseases, with its main active indication being Alzheimer’s disease. As of June 2025, the highest phase reached in development is preclinical[1].

Other names: CB-301(Cantabio)CB 301(Cantabio)CB301(Cantabio)

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on CB-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-301.

Explore the full profile